Grifols, S.A. Share Price

Equities

GRF

ES0171996087

Pharmaceuticals

Market Closed - BME 16:35:30 17/05/2024 BST 5-day change 1st Jan Change
9.886 EUR -0.64% Intraday chart for Grifols, S.A. +5.60% -36.03%

Financials

Sales 2024 * 7.08B 7.7B 607B Sales 2025 * 7.58B 8.24B 649B Capitalization 5.92B 6.44B 507B
Net income 2024 * 416M 452M 35.62B Net income 2025 * 697M 757M 59.68B EV / Sales 2024 * 2.14 x
Net Debt 2024 * 9.25B 10.05B 792B Net Debt 2025 * 8.72B 9.48B 747B EV / Sales 2025 * 1.93 x
P/E ratio 2024 *
12.9 x
P/E ratio 2025 *
9.21 x
Employees 23,000
Yield 2024 *
-
Yield 2025 *
2.66%
Free-Float 79.66%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.64%
1 week+5.60%
Current month+14.34%
1 month+13.68%
3 months-6.78%
6 months-22.22%
Current year-36.03%
More quotes
1 week
9.26
Extreme 9.258
10.44
1 month
8.01
Extreme 8.006
10.44
Current year
6.36
Extreme 6.362
15.63
1 year
6.36
Extreme 6.362
15.92
3 years
6.36
Extreme 6.362
25.94
5 years
6.36
Extreme 6.362
34.31
10 years
6.36
Extreme 6.362
34.31
More quotes
Managers TitleAgeSince
Chief Executive Officer 55 02-05
Director of Finance/CFO 67 31/12/06
Chairman 65 04/04/06
Members of the board TitleAgeSince
Chairman 65 04/04/06
Director/Board Member 68 12/04/00
Director/Board Member 61 26/07/01
More insiders
Date Price Change Volume
17/05/24 9.886 -0.64% 1,896,284
16/05/24 9.95 -2.26% 3,389,335
15/05/24 10.18 +3.37% 7,297,460
14/05/24 9.848 +0.49% 4,954,934
13/05/24 9.8 +4.08% 3,250,764

Delayed Quote BME, May 17, 2024 at 04:35 pm

More quotes
Grifols, S.A. specializes in the research, development, manufacturing and marketing of therapeutic products and medical devices for use in hospitals and medical analysis laboratories. Net sales break down by family of products and services as follows: - products derived from plasma (84.3%): products for use by the pharmaceutical and biotechnology industries; - diagnostic machines and reagents (10.2%): in vitro hemophilic diagnostic equipment, coagulation analyzers, infectious serology reagents, etc. for use primarily by blood banks and transfusion centers; - hospital products (2.4%): non-biological surgical products, radiology and nutritional products, etc. for use by hospital pharmacies; - other (3.1%): primarily intermediate biological products and subcontracted manufacturing services. Net sales are distributed geographically as follows: Spain (5.5%), European Union (13.6%), the United States and Canada (59.1%) and other (21.8%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
9.886 EUR
Average target price
16.81 EUR
Spread / Average Target
+70.01%
Consensus